BXTACCELYON BECOMES GLOBAL DISTRIBUTION PARTNER FOR NEW ONLINE PROSTATE MRI SELF-LEARNING TOOL, MRI PRO, TO ENHANCE PROSTATE CANCER DIAGNOSIS
DATE: BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the revolutionary freehand transperineal prostate biopsy access system, has signed a global agreement with MRI PRO. The partnership will see BXTAccelyon distribute this new, online self-learning tool for prostate MRI diagnostics, designed and developed by a team of specialist MRI radiologists and urologists.
With high-level evidence now confirming prostate MRI’s place in the diagnostic process of prostate cancer detection, as well as adoption of the methodology in NICE, EAU, AUA and national and international urology and radiology guidelines, demand for healthcare professionals experienced in interpreting and accurate reporting of MRI scans is skyrocketing. Gaining the experience that is required for accurate interpretation of prostate MRI is essential, but is difficult to obtain without the availability of immediate histological feedback. MRI PRO addresses this global, unmet need.
Saheed Rashid, Managing Director, BXTAccelyon, comments: “Earlier and better detection of prostate cancer is proven to widen the available treatment options to patients, which will improve outcomes whilst reducing potential adverse side-effects and / or relapse. In recent years, we have made great strides in transforming traditional biopsy techniques, however, it is still the case that we currently diagnose cancers that are harmless, leading to unnecessary investigations and operations, and we miss cancers that are harmful.
“Prostate MRI represents the next stage in prostate cancer diagnosis, but there is an unmet demand for education and training in MRI imaging and interpretation by all healthcare professionals, including in nursing, junior doctor, urologist and radiologist training. BXTAccelyon is therefore proud to be the global distribution partner for this online learning platform that is paving the way for MRI education.”
MRI PRO is a subscription based e-learning platform that allows healthcare professionals to test themselves on 300 of the highest quality histology-verified prostate MRI cases. All cases on MRI PRO are acquired and reported to PIRADS v.2 specifications, using 3T magnets and expert prostate MRI radiologists and experts. Users submit their answers on PIRADS score, location of index lesions and staging information for each case, and get instant feedback on how they did, including access to the actual biopsy report. The platform provides users with performance over time, with a percentage score of correct answers for the last 20 and 50 cases reviewed.
El método MRI PRO está acreditado por el European Accreditation Council for Continuing Medical Education (EACCME), la American Medical Association (AMA), el Royal Australasian College of Surgeons, y el Royal Australian and New Zealand College of Radiologists para conseguir puntos CME.
Associate Professor Jeremy Grummet of MRI PRO, adds: “As an organisation, we are committed to improve the safety, precision, and efficiency of prostate cancer biopsy, and recognise the hugely important role MRI diagnostics can play. However, ensuring all healthcare professionals can gain the necessary experience to maximise the value of this methodology within the prostate cancer pathway, is key. These are values which are also closely mirrored by the team at BXTAccelyon; their approach to training whole prostate cancer teams in the PrecisionPoint biopsy device is one we welcome, and are keen to mirror. We are pleased to partner with BXTAccelyon with the aim of improving the overall patient experience and delivering the best possible health outcomes.”
BXTAccelyon will be showcasing MRI PRO at its monthly workshops to train healthcare professionals on the PrecisionPointTM Transperineal Access System method at the Cancer Centre at Guy’s and St Thomas’ in London and Southmead Hospital, Bristol from February 2020.